Progeria triple-therapy findings ‘disappointing’

Pravastatin and zoledronic acid provide no additional clinically relevant benefit to lonafarnib monotherapy for patients with Hutchinson-Gilford progeria syndrome, study findings indicate.
Source: MedWire News - Category: Consumer Health News Tags: Cardiology Source Type: news

Related Links:

In conclusion, our results suggest that SIM may serve as a promising treatment with TAM for improving the efficacy against estrogen receptor-positive (ER+) breast cancer.Graphical abstract
Source: Toxicology Reports - Category: Toxicology Source Type: research
Publication date: Available online 18 October 2019Source: Canadian Journal of CardiologyAuthor(s): Dirk G. Struijk
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Background and aims: Atrial fibrillation (AF) is a major cause of ischemic stroke; however, detailed clinical data and prognostic factors for stroke patients with AF are lacking in Korea. We aimed to investigate clinical information and factors associated with functional outcomes of stroke patients with AF from the Korean nationwide ATrial fibrillaTion EvaluatioN regisTry in Ischemic strOke patieNts (K-ATTENTION) database.Methods: From January 2013 to December 2015, consecutive clinical information from acute stroke patients with AF or history of AF was collected from 11 centers in Korea. Collected data included demographi...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Abstract NMR measurements of 19F chemical shift anisotropy and 1H-19F dipolar couplings provide unprecedented information on the molecular orientations of two fluorine-containing statin drugs within the heterogeneous environment of reconstituted high-density lipoprotein (rHDL) nanoparticles, a drug delivery system under clinical investigation. PMID: 31626247 [PubMed - as supplied by publisher]
Source: Chemical Communications - Category: Chemistry Authors: Tags: Chem Commun (Camb) Source Type: research
Source: Journal of NeuroImmune Pharmacology - Category: Drugs & Pharmacology Source Type: research
Changes in clinical guidelines have increased the number of people eligible to take statins. In many countries, the majority of people taking the drugs do so for primary prevention.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Publication date: Available online 14 October 2019Source: Microchemical JournalAuthor(s): A. Parsa, H. HeliAbstractWrinkled nanostructure of nickel was electrodeposited from a deep eutectic solvent comprising choline chloride and urea (reline) under golvanostatic conditions. Field emission scanning electron microscopic images were taken to evaluate the shape and size of the nickel nanostructure. The nickel nanostructure was then converted into the corresponding oxides, and the kinetics of charge transfer across the interface of the nanostructured oxides/an alkaline electrolyte was then studied. The electron transfer coeffi...
Source: Microchemical Journal - Category: Chemistry Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
THURSDAY, Oct. 17, 2019 -- Many people who take cholesterol-lowering statins may not benefit from them, researchers say. Drugs like atorvastatin (Lipitor) and fluvastatin (Lescol) provide little value to people without heart disease, new research...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Title: For Kids With Genetic Condition, Statins May Be LifesaversCategory: Health NewsCreated: 10/16/2019 12:00:00 AMLast Editorial Review: 10/17/2019 12:00:00 AM
Source: MedicineNet Cholesterol General - Category: Cardiology Source Type: news
More News: Cardiology | Health | Heart | Pravastatin | Reclast | Statin Therapy | Study | Zometa